Please login to the form below

Not currently logged in
Email:
Password:

Teva/Pfizer settle Neurontin suit

Teva Pharmaceutical has announced it has settled a patent dispute with Pfizer concerning generic versions of Pfizer's Neurontin (gabapentin) – a drug marketed for pain management and the treatment of epilepsy

Teva Pharmaceutical has announced it has settled a patent dispute with Pfizer concerning generic versions of Pfizer's Neurontin (gabapentin) – a drug marketed for pain management and the treatment of epilepsy.

The Israel-based generic manufacturer said litigation related to capsules and tablets sold by the company and its subsidiary Ivax Pharmaceuticals has been 'dismissed' by United States District Court for the District of New Jersey in accordance with a settlement reached between the two parties.

Teva did not reveal financial details of the settlement, but reports have suggested it is less than $100m.

Pfizer had filed litigation claiming that Teva's generic version infringed a patent that expires in 2017, with the US-based drugmaker seeking compensation for profit lost due to competition.

A generic gabapentin was launched by Ivax in 2004. Teva later purchased Ivax in 2006.

1st June 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...
Mainimage2
The role of digital health technology tools in supporting medical adherence
How DHT-based digital interventions can help to support patients and improve adherence...